Edition:
India

Eagle Pharmaceuticals Inc (EGRX.OQ)

EGRX.OQ on NASDAQ Stock Exchange Global Market

65.02USD
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
$65.02
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
104,863
52-wk High
$97.14
52-wk Low
$45.05

Select another date:

Tue, Jan 9 2018

BRIEF-Iridian Asset Management LLC Reports 10.1 Pct Passive Stake In Eagle Pharmaceuticals As Of Dec. 31, 2017 - SEC Filing‍​

* IRIDIAN ASSET MANAGEMENT LLC REPORTS 10.1 PERCENT PASSIVE STAKE IN EAGLE PHARMACEUTICALS INC AS OF DEC. 31, 2017 - SEC FILING‍​ Source text: (http://bit.ly/2En48mt) Further company coverage:

BRIEF-Iridian Asset Management Reports 10.1 Pct Passive Stake In Eagle Pharmaceuticals

* IRIDIAN ASSET MANAGEMENT REPORTS 10.1 PERCENT PASSIVE STAKE IN EAGLE PHARMACEUTICALS AS OF DEC 31, 2017 - SEC FILING‍​ Source text: (http://bit.ly/2AG5uGB) Further company coverage:

BRIEF-Eagle Pharmaceuticals Commences Pivotal Study For Fulvestrant

* EAGLE PHARMACEUTICALS COMMENCES PIVOTAL STUDY FOR FULVESTRANT

BRIEF-Eagle Pharmaceuticals Q3 earnings per share $0.98

* Eagle Pharmaceuticals Inc reports third quarter 2017 results

Eagle Pharma gets tentative FDA approval for Lilly's Alimta version

Eagle Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration tentatively approved its diluted version of Eli Lilly and Co's blockbuster cancer drug Alimta.

UPDATE 1-Eagle Pharma gets tentative FDA approval for Lilly's Alimta version

Oct 27 Eagle Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration tentatively approved its diluted version of Eli Lilly and Co's blockbuster cancer drug Alimta.

FDA tentatively approves Eagle Pharma's cancer drug

Oct 27 Eagle Pharmaceuticals Inc said on Friday that the U.S. Food and Drug Administration tentatively approved its injectable drug to treat a most common type of lung cancer and a cancer of mesothelial tissue.

BRIEF-EAGLE PHARMACEUTICALS RECEIVES TENTATIVE FDA APPROVAL FOR PEMFEXY

* EAGLE PHARMACEUTICALS RECEIVES TENTATIVE FDA APPROVAL FOR PEMFEXY (PEMETREXED INJECTION) READY-TO-DILUTE

BRIEF-Eagle Pharmaceuticals licenses Japanese rights for Bendamustine HCl

* Eagle Pharmaceuticals licenses Japanese rights for Bendamustine Hydrochloride ready-to-dilute and rapid infusion injection products to Symbio Pharmaceuticals Limited

BRIEF-EAGLE PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS OF STUDY CONDUCTED TO EVALUATE NEUROPROTECTIVE EFFECTS OF RYANODEX SECONDARY TO NERVE AGENT EXPOSURE

* EAGLE PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS OF STUDY CONDUCTED TO EVALUATE NEUROPROTECTIVE EFFECTS OF RYANODEX SECONDARY TO NERVE AGENT EXPOSURE

Select another date: